Trust Point Inc. Has $473,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Trust Point Inc. grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,175 shares of the pharmaceutical company’s stock after buying an additional 59 shares during the quarter. Trust Point Inc.’s holdings in Vertex Pharmaceuticals were worth $473,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Childress Capital Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 4.6% in the 4th quarter. Childress Capital Advisors LLC now owns 804 shares of the pharmaceutical company’s stock valued at $324,000 after buying an additional 35 shares in the last quarter. Alliance Wealth Advisors LLC UT acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $377,000. Optas LLC raised its stake in shares of Vertex Pharmaceuticals by 7.9% in the 4th quarter. Optas LLC now owns 874 shares of the pharmaceutical company’s stock valued at $352,000 after buying an additional 64 shares in the last quarter. Resonant Capital Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 3.3% in the 4th quarter. Resonant Capital Advisors LLC now owns 1,267 shares of the pharmaceutical company’s stock valued at $510,000 after buying an additional 41 shares in the last quarter. Finally, Catalina Capital Group LLC raised its stake in shares of Vertex Pharmaceuticals by 5.9% in the 4th quarter. Catalina Capital Group LLC now owns 873 shares of the pharmaceutical company’s stock valued at $352,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent analyst reports. Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Finally, Bank of America dropped their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Stock Up 1.3 %

Vertex Pharmaceuticals stock opened at $488.44 on Thursday. The company’s 50 day simple moving average is $435.03 and its 200 day simple moving average is $462.56. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a market capitalization of $125.79 billion, a price-to-earnings ratio of -245.45, a PEG ratio of 2.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm earned $3.67 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.